Journal of Clinical Oncology publication of pivotal clinical trial results for narsolimab in HSCT-TMA.
Omeros Corporation announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment
The manuscript – "Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy" – will be published in an upcoming volume of the Journal of Clinical Oncology (JCO) and was made available online by JCO, the flagship publication of the American Society of Clinical Oncology.
See - DOI: 10.1200/JCO.21.02389 Journal of Clinical Oncology - published online before print April 19, 2022. PMID: 35439028 "Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy".-Samer K. Khaled, MD; Kathleen Claes, MD, PhD; Yeow Tee Goh, MBBS, MMed, Yok Lam Kwong, MD,; Nelson Leung, MD; Wlodzimierz Mendrek, MD; et al.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins